Risk Reduction for Alzheimer's Disease
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 513 participants.
Also called NCT02913664
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Phase 2/3
- Enrolled
- 513 participants
- Sponsor
- Registry
-
NCT02913664
-
- Other papers using this trial's data
- Effects of Exercise and Intensive Vascular Risk Reduction on Cognitive Function in Older Adults: A Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02913664. Randomized; single masking; primary purpose prevention. Start 2017-02-02 (actual); primary completion 2021-11-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Risk Reduction for Alzheimer's Disease
- Acronym
- rrAD
- Condition
- Cognitively Normal Older Adults
- Condition
- Hypertension
- Condition
- Subjective Cognitive Decline
- Condition
- Family History of Alzheimer's Disease
- Intervention (Drug)
- Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine)
- Intervention (Behavioral)
- Aerobic Exercise Training
- Intervention (Other)
- Usual Care
- Intervention (Behavioral)
- Stretching Exercise
- Lead sponsor
- University of Texas Southwestern Medical Center
- Collaborator
- Texas Health Resources
- Collaborator
- University of Kansas Medical Center
- Collaborator
- Washington University School of Medicine
- Collaborator
- Pennington Biomedical Research Center
- Collaborator
- Michigan State University
Record details
- Record id
cardio:ct-nct02913664- Content hash
26824315d567ec6909525d0790cb815ff951fc6f0aa8a87a3f261fc53b005d14